Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference
More News related to BMY
- Asterand Announces Extension of Agreement with Bristol-Myers Squibb
- U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
- Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
- Bristol-Myers (BMY) To Spin-Off Mead Johnson (MJN) Holdings
More News related to Press Releases
- Windstream (WIN) to Acquire Iowa Telecom (IWA) for 0.804/Shares Plus $7.90 in Cash; Deal Valued at $1.1B
- Barnes & Noble (BKS) Reports In-Line Loss of $0.30; Lowers FY Guidance
- Q3 Revised GDP: Up 2.8%, Inline with Consensus; Personal Consumption: 2.9%
- Medtronic (MDT) Tops Q3 Views; Guides FY10 EPS Above the Street
- HJ Heinz (HNZ) Tops Q2 EPS by 6c; Raises FY10 EPS Guidance
NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will present at a Credit Suisse healthcare conference on Thursday, November 12, 2009 in Phoenix, Arizona. Jean-Marc Huet, executive vice president and chief financial officer of Bristol-Myers Squibb, will make a formal presentation about the company at 10:30 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the presentation will be available later that day.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com.
Source: Bristol-Myers Squibb Company
Related Categories
Press ReleasesStocks Mentioned
-0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
